Under the Medicaid Drug Rebate Program, Medicaid programs must cover nearly all of a participating manufacturers FDA-approved drugs for medically accepted indications
Subcutaneous planning from a 50 mg vial reconstituted with 3.0 mL BAC water (~16.7 mg/mL) Phase Days 12 (tolerance) Daily dose 2.5 mg once daily Units on U-100 syringe 15 units Volume 0.15 mL Phase Days 3+ (standard) Daily dose 5 mg once daily Units on U-100 syringe 30 units Volume 0.30 mL Phase Split option (BID) Daily dose 2.5 mg twice daily Units on U-100 syringe 15 units each Volume 0.15 mL each These subcutaneous examples come from informal research discussions
It is important to emphasise that these proposals are based almost entirely on preclinical data principally in vitro (cell culture) experiments and animal studies and have not been reliably demonstrated in robust human clinical trials: Stimulation of follicle enlargement: Laboratory studies suggest GHK-Cu may increase hair follicle size, potentially counteracting the miniaturisation associated with androgenetic alopecia (pattern hair loss), though this has not been confirmed in humans
Regarding light-curing exposure time, a study concluded that on a polymerization time less than 40 s, and a temperature of about 37 C in the oral cavity, resin-matrix composites are never polymerized to their full extent, as the propagation of the cross-linking reaction drastically reduces the mobility of monomers [38]
At Facelit Clinic , we follow rigorous safety standards to minimize any risk of side effects
Those with heart disease or high risk should discuss supplementation with their cardiologist